VEGFbTM Has Been Granted Orphan Drug Designation By The FDA For The Treatment Of Advanced Melanoma

PhiloGene, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to VEGFb for the treatment of patients with advanced melanoma. This approval is for a larger subset of melanoma patients than was requested, and includes melanoma in stages IIb through IV.

More: continued here

Filed under: Cancer on July 25th, 2008